| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
In SKOV-33 cells, selenium (100–400 μM; 3 days) promotes inertness [1]. Cellular inertness mediated by caspase-3 is induced by 100–400 μM of selenium methyl ester for three days [1]. Examination [1]
|
|---|---|
| ln Vivo |
Nude mice given FaDu and A253 head and neck xenografts tumor activity have increased CDDP and cyclophosphamide resistance when treated with selenium selenium (0.2 mg/mouse; face; once daily for 14 days)[2]. For ten months, methyltyrosine (0.75 mg/kg body weight per day) was administered intraperitoneally (IT) to mice suffering from Alzheimer's disease (AD). Reduces oxidative intermediates, neural pathways, and levels of various metal ions. It also inhibits the expression of precursor protein APP and beta-enzyme (BACE1), which lowers the production of amyloid-beta peptide (Aβ), forms fragmented tau hyperphosphorylation, and forms neurofibrillary tangles by promoting protein phosphatase 2A (PP2A) activity (NFT). This protects synaptic proteins and neuronal activity, which in turn improves spatial learning and memory deficits in AD models [3].
|
| Cell Assay |
Apoptosis Analysis[1]
Cell Types: SKOV-3 Cell Tested Concentrations: 100, 200, 400 μM Incubation Duration: 3 days Experimental Results: Resulted in a significant increase in the accumulation of Sub-G1 phase, which occurred in a SeMSC concentration and culture time dependence. Western Blot Analysis[1] Cell Types: SKOV-3 Cell Tested Concentrations: 100, 200, 400 μM Incubation Duration: 3 days Experimental Results: Resulted in diminished expression of the 32 kDa form of procaspase-3. |
| Animal Protocol |
Animal/Disease Models: Female athymic nude mice (bearing human A253 and FaDu squamous cell carcinoma xenografts) [ 2]
Doses: 0.2mg/only Route of Administration: po; ]. one time/day for 14 days (7 days before and 7 days after cyclophosphamide or CDDP, 14 days total) Experimental Results: |
| References |
|
| Additional Infomation |
Se-methyl-L-selenocysteine is an L-alpha-amino acid compound having methylselanylmethyl as the side-chain. It has a role as an antineoplastic agent. It is a Se-methylselenocysteine, a non-proteinogenic L-alpha-amino acid and a L-selenocysteine derivative. It is a conjugate base of a Se-methyl-L-selenocysteinium. It is a conjugate acid of a Se-methyl-L-selenocysteinate. It is an enantiomer of a Se-methyl-D-selenocysteine. It is a tautomer of a Se-methyl-L-selenocysteine zwitterion.
Methylselenocysteine has been used in trials studying the prevention of Prostate Carcinoma and No Evidence of Disease. Se-Methylselenocysteine is a metabolite found in or produced by Escherichia coli (strain K12, MG1655). Se-methylselenocysteine has been reported in Bos taurus, Astragalus bisulcatus, and Euglena gracilis with data available. Methylselenocysteine is a naturally occurring organoselenium compound found in many plants, including garlic, onions, and broccoli, with potential antioxidant and chemopreventive activities. Se-Methyl-seleno-L-cysteine (MSC) is an amino acid analogue of cysteine in which a methylselenium moiety replaces the sulphur atom of cysteine. This agent acts as an antioxidant when incorporated into glutathione peroxidase and has been shown to exhibit potent chemopreventive activity in animal models. |
| Molecular Formula |
C4H9NO2SE
|
|---|---|
| Molecular Weight |
182.081
|
| Exact Mass |
182.979
|
| CAS # |
26046-90-2
|
| Related CAS # |
Se-Methylselenocysteine hydrochloride;863394-07-4
|
| PubChem CID |
147004
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
314.1±37.0 °C at 760 mmHg
|
| Melting Point |
177 °C(dec.)
|
| Flash Point |
143.7±26.5 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| LogP |
-0.89
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
8
|
| Complexity |
86.1
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[Se]C[C@@H](C(=O)O)N
|
| InChi Key |
XDSSPSLGNGIIHP-VKHMYHEASA-N
|
| InChi Code |
InChI=1S/C4H9NO2Se/c1-8-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)/t3-/m0/s1
|
| Chemical Name |
(2R)-2-amino-3-methylselanylpropanoic acid
|
| Synonyms |
Se-Methylselenocysteine Se-MSC MSeCSeMCys SeMSCSe MSC
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~83.33 mg/mL (~457.66 mM)
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (274.60 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4921 mL | 27.4605 mL | 54.9209 mL | |
| 5 mM | 1.0984 mL | 5.4921 mL | 10.9842 mL | |
| 10 mM | 0.5492 mL | 2.7460 mL | 5.4921 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04952129 | ACTIVE, NOT RECRUITING | Drug: Selenomethionine Drug: Methylselenocysteine |
Colorectal Adenoma | University of Auckland, New Zealand | 2022-05-06 | Phase 1 |
| NCT00489372 | COMPLETED | Drug: Se-methyl-seleno-L-cysteine Other: placebo Other: pharmacological study Other: laboratory biomarker analysis |
Healthy, no Evidence of Disease | National Cancer Institute (NCI) | 2007-07 | Phase 1 |
| NCT01497431 | COMPLETED | Dietary Supplement: Selenium Other: Placebo Other: Laboratory Biomarker Analysis |
No Evidence of Disease Prostate Carcinoma |
National Cancer Institute (NCI) | 2011-11 | Phase 1 |
| NCT01611038 | COMPLETED | Dietary Supplement: Methylselenocysteine Dietary Supplement: Placebo |
Breast Cancer Prostate Cancer |
Rutgers, The State University of New Jersey | 2011-10 | Not Applicable |
| NCT00829205 | WITHDRAWN | Biological: filgrastim Biological: rituximab Dietary Supplement: Se-methyl-seleno-L-cysteine |
Lymphoma | Cancer Research UK | 2009-01 | Phase 1 Phase 2 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
